MARKET

CODX

CODX

Co-Diagnostics Inc
NASDAQ
2.890
+0.040
+1.40%
Closed 16:00 01/27 EST
OPEN
2.860
PREV CLOSE
2.850
HIGH
2.920
LOW
2.832
VOLUME
72.03K
TURNOVER
129.83K
52 WEEK HIGH
7.35
52 WEEK LOW
2.260
MARKET CAP
89.35M
P/E (TTM)
6.26
1D
5D
1M
3M
1Y
5Y
Co-Diagnostics, Inc. (NASDAQ:CODX) Analysts Are More Bearish Than They Used To Be
Market forces rained on the parade of Co-Diagnostics, Inc. ( NASDAQ:CODX ) shareholders today, when the analysts...
Simply Wall St. · 12/03/2022 12:25
Co-Diagnostics, Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting on December 1, 202...
PR Newswire · 11/30/2022 15:00
Co-Diagnostics Third Quarter 2022 Earnings: Misses Expectations
Co-Diagnostics ( NASDAQ:CODX ) Third Quarter 2022 Results Key Financial Results Revenue: US$5.09m (down 83% from 3Q...
Simply Wall St. · 11/16/2022 10:17
HC Wainwright & Co. Maintains Buy on Co-Diagnostics, Lowers Price Target to $6
Benzinga · 11/14/2022 11:26
BRIEF-Co-Diagnostics Inc Reports Third Quarter 2022 Financial Results
Reuters · 11/10/2022 21:40
Co-Diagnostics Q3 EPS $(0.04), Inline, Sales $5.10M Miss $7.98M Estimate
Benzinga · 11/10/2022 21:19
Co-Diagnostics GAAP EPS of -$0.04, revenue of $5.1M
Seekingalpha · 11/10/2022 21:16
-- Earnings Flash (CODX) CO-DIAGNOSTICS Reports Q3 Revenue $5.1M
-- Earnings Flash (CODX) CO-DIAGNOSTICS Reports Q3 Revenue $5.1M
MT Newswires · 11/10/2022 16:27
More
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

Webull offers kinds of Co-Diagnostics Inc stock information, including NASDAQ:CODX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CODX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CODX stock methods without spending real money on the virtual paper trading platform.